TFS Trial Form Supportsp. z o.o.
Research and experimental development on biotechnology
Overview
Financials
Revenue history (in k)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 — this may be an accounting template or the first year of the regime.
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2009-05-27. Active
26 2370 0008 0000 0000 2104 3005- 74 2370 0008 0000 0000 2104 3014
- 25 2370 0008 0000 0000 2104 3023
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
If the company has a multi-member management board, the company may be represented and declarations of will may be made on its behalf by the President of the Management Board independently, or by two members of the management board acting jointly.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Tfs International Clinical Development Services Ab | 12,573 | $169,813.61 | 99% |
Others | 127 | $1,715.29 | 1% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Katarina Ageborg (61)  | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Per Gösta Magnusson (72) | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Anders Slettengren (58) | Natural person holding a senior management position in a parent entity (e.g. parent company). | |
Magnus Stephesen (46) | Natural person holding a senior management position in a parent entity (e.g. parent company). |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| Orphinic ScientificS.A. | $518,429.97 | orphinic.com | ||
| Proper Medical Writingsp. z o.o. | $464,661.64 | propermedicalwriting.com | ||
| Medicofarma BiotechS.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Explorna Therapeuticssp. z o.o. | $304,662.00 | explorna.com | ||
| Frontline BiosciencesS.A. | $219,186.29 | frontlinebiosciences.com | ||
| AI Corelabsp. z o.o. | $128,365.55 | aicorelab.com | ||
| ModicaP.S.A. | $103,400.72 | modica.bio | ||
| WPD Pharmaceuticalssp. z o.o. | $90,822.78 | wpdpharmaceuticals.com | ||
| WPD PharmaceuticalsS.A. | $87,561.70 | wpdpharmaceuticals.pl |
Change history
| Date | Event | |
|---|---|---|
| 2019-06-04 | Address change (Ul. Iłżecka 26e, 02-135, Warszawa → Ul. Grójecka 208/2 Piętro, 02-390, Warszawa) | |
| 2015-06-18 | Address change (Ul. Dolna 10/2, 00-774, Warszawa → Ul. Iłżecka 26e, 02-135, Warszawa) | |
| 2015-04-07 | Address change (Iłżecka 26 E, 02-135, Warszawa → Ul. Dolna 10/2, 00-774, Warszawa) | |
| 2015-04-07 | PKD change (Removed: 58.11.Z, 58.12.Z, 58.14.Z, 58.19.Z, 62.02.Z, 62.03.Z, 62.09.Z, 63.11.Z, 63.12.Z, 69.20.Z, 70.21.Z, 71.20.A, 74.10.Z, 74.30.Z, 77.33.Z, 77.40.Z, 78.20.Z, 82.19.Z, 82.20.Z, 82.30.Z, 82.99.Z, 85.59.B, 85.60.Z, 91.01.B, 95.11.Z, 95.12.Z, 95.21.Z) | |
| 2013-11-19 | Share capital change (5,000.00 PLN → 635,000.00 PLN) |
FAQ
Last updated: 2026-04-17